IBCD 20182018-07-27T09:19:09+00:00

Regulators and academics paving new paths
for cancer clinical research

Roberto Sagado - Denis Lacombe

IBCD 2018 will explore routes through the constantly evolving scientific, methodological and regulatory environment for drug and biomarker development. The EORTC, NCI, EMA, and AACR with the involvement of FDA and PMDA and Health Technology Assessment specialists endeavour to build upon the recommendations and action points decided upon at the IBCD2016-edition. Topics, such as, Health Technology Assessment (HTA) of biomarker assays, comparative effectiveness research and the translation of findings of clinical trials into daily practice will be addressed.  The conference will also discuss the emergence of new regulatory routes to approve new anti-cancer agents based on biomarkers, demonstrating the relevance and feasibility of innovative clinical trial designs.



Setting the Scene

09.00 – 09.30 Introduction
Speakers: D. Lacombe and R. Salgado

Session 1


Evidence driven healthcare systems: the way forward

Chairs: R. Canetta & H.K. Lyerly

9.30 – 9.50 Current trends for molecular and immunological profiling (immunologic aspects)
speakers: D. Rimm
9.50 – 10.10 Current trends for molecular and immunological profiling (molecular diagnostic aspects)
speakers: TBC
10.10 – 10.30 Compassionate Use and Pre-Approval Access (CUPA): matching patients to new therapies
Speakers: A. Bateman-House
10.30 – 10.50 The impact of drug access upon survival in Europe
Speakers: L. Bergman
10.50 – 11.10 Patient Access to new therapies: HTA perspective
Speakers: A. Makady
11.10 – 11.30 Coffee Break
11.30 – 12.30 Panel discussion
Panelists: B. Besse, L. Osipienko, speakers and chairs
12.30 – 13.30 Lunch Break

Session 2


Challenges of Clinical Trial Design: New Perspectives

Chairs: T. Lively & F. Pignatti

13.30 – 13.45 NCI MATCH trial: Lessons learnt
Speaker: L. Harris
13.45 – 14.00 Japanese precision medicine trials: the way forward
Speaker: S. Nagai
14.00 – 14.15 EORTC SPECTA: Challenges of a European platform for precision medicine
Speaker: V. Golfinopoulos
14.15 – 14.30 Regulatory issues on molecular testing
Speaker: TBC
14.30 – 14.45 Are companion diagnostic useful?
Speaker: M. Thomas
14.45 – 15.15 Coffee Break
15.15 – 16.30 Panel Discussion
Panelists: J. Beaver, O. Collignon, I. Cree, P.Hedge, speakers and chairs

Session 3


Generating the scientific evidence: the challenges in implementing to daily practice

Chairs: J. Bogaerts  & D. Solit 

09.30 – 09.45 Liquid biopsy: validation of cell free DNA profiling
Speakers: C. Smith
9.45 – 10.00 Germline testing to dictate drug response
speakers: TBC
10.00 – 10.15 Centralized testing vs local testing from the industry perspective
Speakers: M. Savage
10.15 – 10.30 Centralized testing vs local testing from the academic perspective
Speakers: E. Voest
10.30 – 10.45 Data sharing: How can we leverage big data?: Lessons learned from the surrogacy work of the ICECaP Working Group
Speakers: C. Sweeney
10.45 – 11.15 Coffee Break
11.15 – 12.30 Panel Discussion
Panelists: J. Beaver, G. Nichols and speakers
12.30 – 13.00 Closing Remarks
Speaker: D. Lacombe and R. Salgado


Online registration opens on 17 May 2018 and closes on 15 November 2018*
* 10.00 AM Central European Time (CET)

Registration will close in


Graph ITI

We welcome your support for this meeting which will foster new forms of partnerships between academia, industry, regulatory, health technology assessment bodies and payers adding value to tomorrow’s personalized cancer treatments for patients in a daily practice setting.

Booking form


We wish to thank our sponsors for their generous support.


Janssen Oncology

Media Partners


Hotel Accommodation

  • Radisson Blu Royal Hotel, Brussels

  • +32 2 219 28 28

Hotel bookings are not managed by EORTC

A limited number of rooms have been reserved for this event at the Radisson Blu Royal Hotel, Brussels.

The deadline for hotel reservations is 12 November 2018.
Accommodation requests received after 12 November will be processed on a space-available basis and may be subject to higher rates. Please contact the hotel for any further information and/or confirmation.